Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2001

View Archived Issues

Vaccine for group A Streptococcus enters phase I/II in Canada

OGS reports substantial progress on all fronts during past year

Unigene reports oral delivery of PTH analog

Lynx Therapeutics and UroGene collaborate to identify anticancer genes

MGI Pharma commences new phase II trial of irofulven for treatment of ovarian cancer

Immunex reports data from two of three Nuvance phase II studies; third study continues

FDA approves Cygnus' glucose monitoring device

Iomed and Santen to develop treatment of posterior eye diseases

Positive phase III results reported for Enbrel in psoriatic arthritic patients

IDDS commences phase I/II trial of nasal ketamine for treatment of acute pain

Novel APP inhibitor shows kinin-dependent reduction in MI size

Noven's Estradot transdermal HRT approved in the Netherlands

DuPont Pharmaceuticals' roxifiban study amended

Several agents compared in structural reorganization of myocardial collagen post-MI

Adenosine A2A receptor agonist reduces infarct size in dog model

VPI fails to show better cardioprotection than ACE inhibitor in MI rat model

Tetrahydrobiopterin shows cardioprotective activity in experimental model

New data presented for Japan Tobacco's novel cardioprotective drug

Dainippon's new elastase inhibitor offers potential for critical care of ARDS and septic shock

New polypeptides useful as vaccines for bacterial infections

Abbott discovers new potassium channel openers useful for bladder overactivity, etc.

Novartis describes new series of purine derivatives for inflammatory or allergic conditions

New compounds useful for CNS disorders patented by Ortho-McNeil

New azaindolinone derivatives patented by Zenyaku Kogyo

Multivalent compounds claimed by P&G useful for hair loss, etc.

Novel cPLA2 inhibitors with antiinflammatory activity reported by Nippon Soda

AVI BioPharma's antisense agent slows tumor growth in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...